GrifolsMEX:GRFP N 83 EBITDA Margin % is 20.76% as of Mar. 2026, which is 14% below its 10-year median of 24.23. GuruFocus rates MEX:GRFP N with a GF Score™ of 83/100 and a GF Value™ of MXN154.24. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Grifols ranks better than 71.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Grifols's EBITDA for the
three
months ended in Mar. 2026 was MXN7,359 Mil. Grifols's Revenue for the
three
months ended in Mar. 2026 was MXN35,440 Mil. Therefore, Grifols's EBITDA margin for the quarter that ended in Mar. 2026 was 20.76%.
Grifols (MEX:GRFP N) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Grifols EBITDA Margin % Related Terms
Grifols EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Grifols's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GRFP N vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Grifols's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Grifols's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (MEX:GRFP N) has a EBITDA Margin % of 20.76% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Grifols and its competitors. This is 14% below median its historical median of 24.23. Over the past decade, Grifols' EBITDA Margin % has ranged from 17.72 to 28.32. According to the industry distribution chart, Grifols ranks #271 out of 955 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Grifols' EBITDA Margin % too high?
Grifols' current EBITDA Margin % of 20.76% is 14% below median its 10-year median of 24.23. Over the past 10 years, this metric has ranged from a low of 17.72 to a high of 28.32. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Grifols' value of 20.76% is 67.6% above this industry median. Based on the distribution chart, Grifols ranks #271 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #271 out of 955 companies for EBITDA Margin %. This puts Grifols in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Grifols' value of 20.76% is 67.6% above this benchmark. Historically, Grifols' own EBITDA Margin % has ranged from 17.72 to 28.32 over the past decade. While the company's 10-year median is 24.23 vs. the industry median of 12.39, Grifols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current EBITDA Margin % of 20.76% is 67.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current EBITDA Margin % is 20.76%, which is 14% below median its own 10-year median of 24.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current EBITDA Margin % of 20.76%. The stock's GF Value™ is MXN154.24, compared to a current price of MXN126.63 — trading 17.9% below its estimated fair value. The current EBITDA Margin % is 20.76%, which is 14% below median its 10-year median of 24.23 and 67.6% above the Drug Manufacturers industry median of 12.39. Grifols' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current EBITDA Margin % is 20.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (MEX:GRFP N) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of MXN126.63 is trading 17.9% below its estimated GF Value™ of MXN154.24.
Key valuation signals for MEX:GRFP N:
EBITDA Margin %: 20.76% (14% below median its 10-year median of 24.23)
GF Value™: MXN154.24 vs. price of MXN126.63 (17.9% below fair value)
Industry Position: 67.6% above the Drug Manufacturers median (#271 of 955)
No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score
Get the complete analysis for MEX:GRFP N
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GRFP N has been successfully added to your 
